Unicycive Therapeutics News

Express News | Benchmark Reiterates Speculative Buy on Unicycive Therapeutics, Maintains $3 Price Target

Moomoo 24/7Apr 15 11:00 ET

Buy Rating Affirmed for Unicycive Therapeutics on Strong Trial Progress and Financial Positioning

TipRanksApr 11 15:05 ET

Unicycive Therapeutics to Present at the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference

LOS ALTOS, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the "Company or

GlobeNewswireApr 10 07:03 ET

Express News | Unicycive Therapeutics Shares Are Trading Higher After Piper Sandler Initiated Coverage on the Stock With an Overweight Rating and a Price Target of $9

Moomoo 24/7Apr 4 07:53 ET

Unicycive Therapeutics Initiated at Overweight by Piper Sandler

Unicycive Therapeutics Initiated at Overweight by Piper Sandler

Dow JonesApr 4 07:13 ET

Express News | Piper Sandler Initiates Coverage On Unicycive Therapeutics With Overweight Rating, Announces Price Target of $9

Moomoo 24/7Apr 4 07:03 ET

Unicycive Therapeutics: A Strong Buy on OLC's Potential to Revolutionize Hyperphosphatemia Treatment in CKD

TipRanksApr 4 05:05 ET

Express News | CORRECTION: On Friday, Unicycive Therapeutics Reported Q4 EPS Of $(0.22), Which Missed $(0.17) Estimate

Moomoo 24/7Apr 1 07:04 ET

Unicycive Therapeutics Q4 EPS $(0.35) Misses $(0.17) Estimate

Unicycive Therapeutics (NASDAQ:UNCY) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(0.17) by 105.88 percent. This is a 31.37 percent increase over loss

BenzingaMar 29 00:53 ET

Unicycive Therapeutics GAAP EPS of -$1.28, Revenue of $0.7M

Seeking AlphaMar 28 17:03 ET

Unicycive Therapeutics to Be Featured in Multiple Presentations at the Upcoming European Renal Association Congress

Unicycive Therapeutics, Inc. (Nasdaq: UNCY) today announced that multiple presentations will be delivered on the Company's product candidates, oxylanthanum carbonate (OLC) and UNI-494, at the 61st European Renal Association (ERA) Congress taking place May 23-26, 2024, in Stockholm, Sweden.

GlobeNewswireMar 25 07:03 ET

12 Health Care Stocks Moving In Thursday's Pre-Market Session

GainersAptorum Gr (NASDAQ:APM) shares moved upwards by 47.1% to $6.37 during Thursday's pre-market session. The company's market cap stands at $33.0 million. Nuvectis Pharma (NASDAQ:NVCT) stock moved

BenzingaMar 14 09:06 ET

Express News | Unicycive Therapeutics Shares Are Trading Higher. The Company Announced a $50 Million Private Placement

Moomoo 24/7Mar 14 08:01 ET

Express News | Unicycive Therapeutics Announced It Has Entered Into A Securities Purchase Agreement With Certain Healthcare-focused Institutional Investors For The Sale Of 50,000 Shares Of Its Series B Convertible Preferred Stock At An Offering Price Of $1,000 Per Share

Moomoo 24/7Mar 14 07:10 ET

Unicycive Announces $50 Million Private Placement

LOS ALTOS, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY) (the "Company" or "Unicycive"), a clinical-stage biotechnology company developing therapies for patients with kidney

GlobeNewswireMar 14 07:03 ET

Unicycive Reports Progress in Kidney Injury Treatment Trial

Unicycive Therapeutics, Inc. (NASDAQ: UNCY), a biotech firm focusing on kidney disease therapies, has reported successful completion of the single ascending dose (SAD) portion of its ongoing Phase 1 clinical trial for UNI-494, a drug candidate aimed at preventing delayed graft function (DGF) after kidney transplantation.

Investing.com Mar 13 07:48 ET

Noble Financial Keeps Their Buy Rating on Unicycive Therapeutics (UNCY)

TipRanksMar 11 07:55 ET

Unicycive Therapeutics Completes Patient Enrollment in Pivotal Trial for Investigational Therapy for Hyperphosphatemia

Unicycive Therapeutics (UNCY) said Thursday it has completed patient enrollment in a pivotal clinical trial for Oxylanthanum Carbonate for the potential treatment of hyperphosphatemia in patients with

MT NewswiresMar 8 06:26 ET

12 Health Care Stocks Moving In Thursday's After-Market Session

GainersAinos (NASDAQ:AIMD) shares moved upwards by 100.0% to $2.24 during Thursday's after-market session. The market value of their outstanding shares is at $10.4 million. Talphera (NASDAQ:TLPH) stoc

BenzingaMar 7 16:31 ET

Express News | Unicycive Therapeutics Completes Enrollment In Pivotal Clinical Trial For Oxylanthanum Carbonate

Moomoo 24/7Mar 7 16:12 ET